Premium
Optimal IFN ‐free therapy in treatment‐naïve patients with HCV genotype 1 infection
Author(s) -
Asselah Tarik,
Marcellin Patrick
Publication year - 2015
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.12745
Subject(s) - ns5a , ns5b , medicine , ns3 , hepatitis c virus , virology , hepatitis c , genotype , chronic hepatitis , immunology , hepacivirus , pharmacology , virus , biology , biochemistry , gene
There has been a revolution in the treatment of chronic hepatitis C. Several oral regimens combining direct‐acting antivirals ( DAA s) from different families [ NS 5B nucleotide inhibitors, NS 5B non‐nucleoside inhibitors, NS 5A replication complex inhibitors and NS 3/4A protease inhibitors ( PI )] are under development. These regimens result in an increase in sustained virological response ( SVR ) rates to above 90% and reduce the duration of treatment to twelve weeks or less. As of 2015 several regimens will be approved with additive potencies, without cross‐resistance and with a good safety profile. Remaining issues will include increasing screening and access to care so that HCV may become the first chronic viral infection eradicated worldwide. This review summarizes results obtained with oral DAA s combinations, that have been approved and/or have completed phase III clinical trials for HCV genotype 1 ( HCV ‐1) treatment‐naïve patients.